Venture capitalists increasingly are backing startups that blend computer science and biology in a bid to accelerate drug discovery and the development of novel therapies. Aetion, whose software analyzes how drugs are performing in the real world, comes at the industry from a different angle. Founded in 2013 by Harvard Medical School professors, Aetion allows drug companies and insurers to see how drugs are performing based on real-world evidence beyond a purely lab setting, which could ultimately lead to faster decision-making or reimbursement approval.
Read More
Read More